DPYD Testing: Time to Put Patient Safety First.

[1]  Jonathan A. Busam,et al.  Cost-effectiveness of DPYD Genotyping Prior to Fluoropyrimidine-based Adjuvant Chemotherapy for Colon Cancer. , 2022, Clinical colorectal cancer.

[2]  N. Reddy,et al.  Preemptive pharmacogenetic testing to guide chemotherapy dosing in patients with gastrointestinal malignancies: a qualitative study of barriers to implementation , 2022, BMC cancer.

[3]  Heather B. Blunt,et al.  Pathogenic DPYD variants and treatment-related mortality in patients receiving fluoropyrimidine chemotherapy: A systematic review and meta-analysis. , 2021, The oncologist.

[4]  H. Guchelaar,et al.  Detecting DPD deficiency: when perfect is the enemy of good , 2021, Cancer Chemotherapy and Pharmacology.

[5]  K. Kidwell,et al.  Patients carrying DPYD variant alleles have increased risk of severe toxicity and related treatment modifications during fluoropyrimidine chemotherapy. , 2021, Pharmacogenomics.

[6]  J. Schellens,et al.  Effectiveness and safety of reduced‐dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis , 2019, International journal of cancer.

[7]  Julia M. Barbarino,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update , 2018, Clinical pharmacology and therapeutics.

[8]  S. W. Lam,et al.  The role of pharmacogenetics in capecitabine efficacy and toxicity. , 2016, Cancer treatment reviews.

[9]  H. Rosing,et al.  Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy , 2015, Cancer Chemotherapy and Pharmacology.

[10]  Jane Skinner,et al.  Evaluating Predictive Pharmacogenetic Signatures of Adverse Events in Colorectal Cancer Patients Treated with Fluoropyrimidines , 2013, PloS one.

[11]  S. Amur,et al.  Allopurinol pharmacogenetics: assessment of potential clinical usefulness. , 2011, Pharmacogenomics.

[12]  I. Zineh,et al.  Pharmacogenetics in medicine: barriers, critical factors and a framework for dialogue. , 2009, Personalized medicine.

[13]  A. V. van Kuilenburg,et al.  Pharmacokinetics of 5-Fluorouracil in Patients Heterozygous for the IVS14+1G > A Mutation in the Dihydropyrimidine Dehydrogenase Gene , 2008, Nucleosides, nucleotides & nucleic acids.

[14]  H. Groen,et al.  Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene , 2002, British Journal of Cancer.

[15]  A. V. van Kuilenburg,et al.  Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea. , 1995, DNA and cell biology.